Bavarian Nordic Publishes Scientific Data Supporting the Post-Exposure Protection of IMVAMUNE®
(Thomson Reuters ONE) -
Kvistgård, Denmark, March 15, 2010 - Bavarian Nordic A/S (OMX: BAVA) announced
today that the company has published additional data demonstrating that mice
could be protected from a lethal infection with mousepox, a closely related
virus to smallpox in man, by treating the animals with a single vaccination with
IMVAMUNE® three days after the animals had received the lethal infection.
Moreover, the immune mechanisms associated with this robust post-exposure
protection afforded by IMVAMUNE® were shown to involve both non-specific and
specific arms of the immune system in the early phase, while killer T cells were
required in the later stages to finally recover from the infection.
This work provides additional efficacy data supporting the post-exposure
protection provided by IMVAMUNE®, which is one of the requirements to
potentially support the use of IMVAMUNE® following a declared emergency.
Furthermore, the latest data also provides an insight into immunological
parameters involved in the protection afforded by IMVAMUNE® and as such
addresses one of the requirements under the Animal Rule to elucidate the
mechanism of protection. The Animal Rule is the regulatory path that will be
used to license IMVAMUNE® as a smallpox vaccine for the general population in
the US.
A copy of the paper can be found at
http://dx.plos.org/10.1371/journal.pone.0009659
Anders Hedegaard, President & CEO of Bavarian Nordic, said: "We are pleased to
present additional data supporting the ability of IMVAMUNE® to provide
post-exposure protection against smallpox, which further strengthens the data
package for licensing of IMVAMUNE®."
Contact
Anders Hedegaard, President & CEO. Phone +45 23 20 30 64
Forward-looking statements
This announcement includes "forward-looking statements" that involve risks,
uncertainties and other factors, many of which are outside of our control that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. We undertake no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances after the date made, except as required by law.
About Bavarian Nordic
Bavarian Nordic A/S is a leading industrial biotechnology company developing and
producing novel vaccines for the treatment and prevention of life-threatening
diseases with a large unmet medical need. The company's pipeline is focused in
the three areas; cancer, biodefence and infectious diseases, and includes seven
development programmes. Two programmes are under preparation for Phase III:
PROSTVAC(TM), a therapeutic vaccine for advanced prostate cancer is being
developed under a collaboration agreement with the National Cancer Institute and
IMVAMUNE®, a third-generation smallpox vaccine is being developed under a
contract with the US government.
Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.
For more information please visit www.bavarian-nordic.com
[HUG#1393740]
2010-17-uk: http://hugin.info/100065/R/1393740/350822.pdf
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 15.03.2010 - 03:01 Uhr
Sprache: Deutsch
News-ID 1011371
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Kvistgård
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 84 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bavarian Nordic Publishes Scientific Data Supporting the Post-Exposure Protection of IMVAMUNE®
"
steht unter der journalistisch-redaktionellen Verantwortung von
Bavarian Nordic A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
